The FDA plans to create and staff inspection offices throughout China and India, and possibly other countries, as a means to step up its regulatory enforcement of the growing inventory of drug products being made abroad, commissioner Andrew von Eschenbach told a House Energy and Commerce subcommittee hearing.
From the January 01, 2008 Issue of MM+M - Medical Marketing and Media
